顺铂腹腔热灌注联合紫杉醇对晚期上皮性卵巢癌患者血清肿瘤标志物、免疫指标水平和预后的影响分析
Effects of cisplatin intraperitoneal hyperthermic perfusion combined with paclitaxel on serum tumor markers,immune indicators and prognosis in patients with advanced epithelial ovarian cancer
孔小娟 1谈珍瑜 1乔江 1刘鹏2
作者信息
- 1. 湖南中医药大学第一附属医院妇产科,湖南长沙 410000
- 2. 湖南中医药大学第一附属医院肝胆疝微创外科,湖南长沙 410000
- 折叠
摘要
目的 观察顺铂精准持续循环腹腔热灌注化疗(IPHC)联合紫杉醇治疗晚期上皮性卵巢癌(EOC)的疗效及对患者血清中血管内皮生长因子(VEGF)、可溶性B7H4蛋白表达和预后的影响.方法 选取2019年1月至2021年12月湖南中医药大学第一附属医院收治的104例晚期EOC患者作为观察对象,以随机余数法分为观察组与对照组各52例,对照组行常规静脉化疗,观察组行精准持续循环腹腔热灌注化疗(IPHC)联合静脉化疗.对比两组治疗6个周期后(126d)的临床效果,比较治疗前、治疗126 d后两组肿瘤标志物[糖类抗原125(CA125)、癌胚抗原(CEA)、甲胎蛋白(AFP)、人附睾上皮分泌蛋白4(HE4)]、血清学指标[碱性成纤维细胞生长因子(bFGF)、VEGF、可溶性B7H4蛋白]、T淋巴细胞亚群指标的变化情况,统计两组治疗期间并发症的发生率.结果 治疗126 d后,观察组治疗OR率高于对照组(P＜0.05);治疗后,两组各肿瘤标志物(CA125、CEA、AFP、HE4)、血清相关因子(bFGF、VEGF、B7H4)及CD8+水平均降低,且观察组低于对照组(P＜0.05);两组淋巴细胞水平均升高,且观察组高于对照组(P＜0.05).结论 顺铂IPHC联合紫杉醇治疗晚期EOC疗效显著,能有效地抑制肿瘤生长,提高机体的免疫力,且不增加化疗引起的并发症.
Abstract
Objective To observe the efficacy of cisplatin precision continuous circulating intraperitoneal hyperthermic chemotherapy(IPHC)combined with paclitaxel in treating advanced epithelial ovarian cancer(EOC)and its effects on expressions of serum vascular endothelial growth factor(VEGF)and soluble B7H4 protein and prognosis.Methods We selected 104 patients with advanced EOC treated at our hospital from January 2019 to December 2021 as the study participants.They were randomly divided into two groups:observation group(52 cases)and control group(52 cases).The control group received conventional intravenous chemotherapy while the observation group underwent precision continuous circulating IPHC combined with intravenous chemotherapy.The clinical effect after 6 cycles of treatment(126 days),and the tumor markers[carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),alpha-fetoprotein(AFP),human epididymis protein 4(HE4)],serological indicators[basic fibroblast growth factor(bFGF),VEGF,soluble B7H4 protein]and T lymphocyte subsets indicators before treatment and after 126 days of treatment were compared between the two group,and the incidence rates of complications during treatment in the two groups were calculated.Results After 126 days of treatment,the OR rate of treatment in observation group was higher than that in control group(P＜0.05).After treatment,the levels of tumor markers(CA125,CEA,AFP,HE4),serum-related factors(bFGF,VEGF,B7H4)and CD8+in the two groups were reduced,and the above levels in observation group were lower than those in control group(P＜0.05).The levels of lymphocyte subsets in both groups were enhanced,and the levels in observation group were higher than those in control group(P＜0.05).Conclusions IPHC of cisplatin combined with paclitaxel has a significant efficacy in the treatment of advanced EOC.This approach effectively inhibits tumor growth,enhances immune responses,and does not increase the incidence of chemotherapy-related complications.
关键词
卵巢癌/顺铂/腹腔热灌注/紫杉醇/肿瘤标志物/免疫指标/预后Key words
ovarian cancer/cisplatin/intraperitoneal hyperthermic perfusion/paclitaxel/tumor markers/immune indicators/prognosis引用本文复制引用
基金项目
湖南中医药大学校级科研基金(ZYYDX201753)
出版年
2024
NETL
NSTL
维普
万方数据